

MAY 10 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2


In re Application of

Richard G. Olsen, *et al.*

Serial No. 09/125,841

Filed: January 19, 1999

For: Cellular Immunotherapy



Examiner Ronald B. Schwadron, Ph.D.

Group Art Unit 1600

ASSISTANT COMMISSIONER FOR PATENT EXAMINATIONS  
WASHINGTON, D.C. 20231

**RESPONSE TO NOTICE OF SEQUENCE LISTING REQUIREMENTS  
AND AMENDMENT**

Sir:

Responsive to the outstanding Office action mailed on April 12, 2000 (paper no. 5), Applicants submit herewith a computer-readable copy of a Sequence Listing pursuant to 37 C.F.R. § 1.821, *et seq.*, and a paper copy to be added to the specification by amendment herein. The below-signed attorney hereby attests to the fact that the "Sequence Listing" on the enclosed 3.5" computer diskette as submitted herewith is identical to the paper copy of the "Sequence Listing" added to the specification by amendment herein, pursuant to 37 C.F.R. § 1.821(f). By his signature below, the undersigned attests to the fact that no new matter is introduced into the specification by these amendments or this computer-readable copy of the instant Sequence Listing.

**AMENDMENT**

**IN THE SPECIFICATION**

Page 24, line 6, please insert —(SEQ ID No. : 1)—after the first nucleotide sequence set forth.

Page 24, line 7, please insert —(SEQ ID No. : 2)—after the first nucleotide sequence set forth.

Page 24, line 15, please insert —(SEQ ID No. : 3)—after the first nucleotide sequence set forth.

Page 24, line 16, please insert —(SEQ ID No. : 4)—after the first nucleotide sequence set forth.

Please add the paper copy of the "Sequence Listing" submitted herewith to the specification, separately numbered pursuant to 37 C.F.R. § 1.823.